News & Updates

Show Multimedia Only

GLP-1RA treatment for T2DM may lower risk of surgery in inflammatory bowel disease

16 Jul 2024

Use of glucagon-like peptide-1 receptor agonist (GLP-1RA) appears to reduce the risk of inflammatory bowel disease (IBD)-related surgery in patients with type 2 diabetes mellitus (T2DM) and concomitant ulcerative colitis (UC) or Crohn’s disease (CD), according to a retrospective study.

GLP-1RA treatment for T2DM may lower risk of surgery in inflammatory bowel disease

16 Jul 2024

Tirzepatide reduces sleep apnoea severity in obese patients

16 Jul 2024 by

Treatment with tirzepatide significantly reduced sleep apnoea severity, as shown by a reduction in apnoea-hypopnea index (AHI), among patients with moderate-to-severe obstructive sleep apnoea (OSA) and obesity, regardless of positive airway pressure (PAP) therapy, according to two SURMOUNT-OSA trials presented at ADA 2024.

Tirzepatide reduces sleep apnoea severity in obese patients

16 Jul 2024

Phase II trial of nipocalimab for Sjögren’s disease turns in promising results

15 Jul 2024 by

The investigational monoclonal antibody nipocalimab helped reduce the intensity of Sjögren’s disease in adults in the phase II DAHLIAS trial.

Phase II trial of nipocalimab for Sjögren’s disease turns in promising results

15 Jul 2024

Tofacitinib shows good retention rates in PsA patients

15 Jul 2024

Tofacitinib demonstrates safety and persistence in patients with psoriatic arthritis (PsA) who are mostly refractory to biologic and oral targeted synthetic disease-modifying antirheumatic drugs, results of a study have shown.

Tofacitinib shows good retention rates in PsA patients

15 Jul 2024

Semaglutide may improve NYHA functional class in obesity-related HFpEF

15 Jul 2024 by

Patients with obesity-related heart failure with preserved ejection fraction (HFpEF) treated with semaglutide are more likely to show an improvement in NYHA functional class at 52 weeks than those who received placebo, according to a study.

Semaglutide may improve NYHA functional class in obesity-related HFpEF

15 Jul 2024

Mitapivat breaks new ground as first potential Tx option for NTD thalassemia

15 Jul 2024 by

Mitapivat, a first-in-class, oral, allosteric activator of pyruvate kinase (PK), breaks new ground in the global phase III ENERGIZE study, the first trial to demonstrate the potential of an oral treatment for both alpha- and beta-non-transfusion-dependent thalassemia (NTDT).

Mitapivat breaks new ground as first potential Tx option for NTD thalassemia

15 Jul 2024

Keto diet + exercise: Good for narcoleptics?

15 Jul 2024 by

A 10-week study presented at EAN 2024 has shown that a ketogenic or “keto” diet plus regular physical exercise may be beneficial for people with narcolepsy.

Keto diet + exercise: Good for narcoleptics?

15 Jul 2024

Original New Drug Application Approvals by US FDA (16-30 June 2024)

15 Jul 2024

New drug applications approved by US FDA as of 16-30 June 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-30 June 2024)

15 Jul 2024

Ivonescimab plus chemo confers progression-free survival advantage in pretreated NSCLC

14 Jul 2024

Ivonescimab plus chemotherapy has a tolerable safety profile and appears to significantly prolong progression-free survival (PFS) in patients with nonsmall cell lung cancer (NSCLC) whose disease progressed while receiving EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy, according to interim data from the phase III HARMONi-A study.

Ivonescimab plus chemo confers progression-free survival advantage in pretreated NSCLC

14 Jul 2024

Tofacitinib improves response, lowers mortality in severe UC

13 Jul 2024 by

In patients with acute severe ulcerative colitis (UC), the addition of tofacitinib to corticosteroids results in better response to treatment, reveals a study. This benefit persists beyond 7 days, as shown by the lower rates of medical or surgical rescue therapy at 90 days.

Tofacitinib improves response, lowers mortality in severe UC

13 Jul 2024

News & Updates

Filter by Specialty:

Specialty:

GLP-1RA treatment for T2DM may lower risk of surgery in inflammatory bowel disease

GLP-1RA treatment for T2DM may lower risk of surgery in inflammatory bowel disease

Tirzepatide reduces sleep apnoea severity in obese patients

Tirzepatide reduces sleep apnoea severity in obese patients

Phase II trial of nipocalimab for Sjögren’s disease turns in promising results

Phase II trial of nipocalimab for Sjögren’s disease turns in promising results

Tofacitinib shows good retention rates in PsA patients

Tofacitinib shows good retention rates in PsA patients

Semaglutide may improve NYHA functional class in obesity-related HFpEF

Semaglutide may improve NYHA functional class in obesity-related HFpEF

Mitapivat breaks new ground as first potential Tx option for NTD thalassemia

Mitapivat breaks new ground as first potential Tx option for NTD thalassemia

Keto diet + exercise: Good for narcoleptics?

Keto diet + exercise: Good for narcoleptics?

Original New Drug Application Approvals by US FDA (16-30 June 2024)

Original New Drug Application Approvals by US FDA (16-30 June 2024)

Ivonescimab plus chemo confers progression-free survival advantage in pretreated NSCLC

Ivonescimab plus chemo confers progression-free survival advantage in pretreated NSCLC

Tofacitinib improves response, lowers mortality in severe UC

Tofacitinib improves response, lowers mortality in severe UC